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ABSTRACT
Background: The decrement in utility attributable to side
effects from combination antiretroviral therapy (CART) is
unknown and likely to inﬂuence clinical decisions regarding
CART initiation and cost-effectiveness.
Objective: To quantify the decrement in utility attributable
to side effects from CART.
Methods: We estimated SF-6D utilities (quality-of-life
weights on a scale from 0.29 [worst possible health] to 1.00
[perfect health]) from SF-12 scores among patients with HIV
in the Veterans Aging Cohort Study by using a published and
validated conversion algorithm. We then compared utilities
among patients who: 1) did not have bothersome symptoms
while taking CART; 2) had bothersome symptoms that they
thought might be due to CART; and 3) had bothersome
symptoms that they were conﬁdent were due to CART; we
controlled for other characteristics known to inﬂuence
quality of life and stratiﬁed analyses by CD4 count.
Results: Among 1864 patients with available data, symp-
toms perceived to be attributable to CART were associated
with a mean (95% conﬁdence interval) decrement in utility
of 0.06 (0.05, 0.08) points in univariate analyses and 0.08
(0.06, 0.10) in multivariable analyses, clinically signiﬁcant
differences that are comparable to utility decrements
reported for partial impotence or mild angina. Other
signiﬁcant predictors of changes in SF-6D utilities were
hazardous alcohol consumption, recent drug use, ciga-
rette smoking, homelessness, and African American race
(R2 = 0.12). Stratifying by CD4 count, symptoms attribut-
able to CART side effects decreased utility by 0.03 to 0.08
points.
Conclusions: Symptoms perceived to be related to CART are
associated with a substantial decrement in utility.
Keywords: cost-effectiveness analysis, quality of life, utility
assessment.
Introduction
Combination antiretroviral therapy (CART) has trans-
formed HIV from a rapidly fatal condition to a chronic
disease, and their beneﬁts overwhelmingly exceed their
harms for individuals with pretreatment CD4 counts
below 200 cells/ml [1]. Nevertheless, individuals with
CD4 counts greater than 200 cells/ml have a lower
imminent risk of AIDS-related death, and it remains
unclear whether the beneﬁts of CART would exceed
the harms for such patients. Side effects from CART
are common and clinically signiﬁcant even with newer
and better-tolerated CART regimens [1], and therefore
are likely to be an important component of any aggre-
gate harm from CART.
Quantitatively weighing the harms and beneﬁts of
CART is important because their relative balance may
inform unresolved clinical questions such as the
optimal time for beginning CART, and may also affect
the cost-effectiveness of CART. Nevertheless, quanti-
fying the burden from CART side effects has been
elusive. Although several studies have measured
quality-of-life changes following CART initiation
[2–5], their design was unable to distinguish between
quality-of-life changes due to side effects and quality-
of-life changes due to reductions in disease severity.
Because quantifying harms attributable to CART
requires isolating its negative effects on quality of life
from its other, more positive, consequences, we sought
to investigate the relationship between side effects and
quality of life associated with CART. We used data
from the Veterans Aging Cohort Study (VACS), a large
national study of veterans under care for HIV that
incorporates a thorough inventory of questions regard-
ing symptom burden and quality of life.
Methods
We ﬁrst describe how we identiﬁed patients with sub-
stantial side effects from CART. We then explain how
we measured quality of life. Finally, we describe how
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we compared the quality of life among patients with
and without side effects from CART, controlling for
other characteristics that are important predictors of
quality of life.
Identifying Patients with Side Effects from CART
Veterans Aging Cohort Study is an ongoing eight-site
prospective study of HIV-positive and matched HIV-
negative veterans in care that is designed to assess how
an aging HIV population is impacted by risk factors,
comorbidities, and extended exposure to CART. It is
designed to measure morbidity as well as mortality,
and therefore includes detailed surveys on symptom
burden and quality of life [6]. HIV-positive partici-
pants were asked to complete the HIV Symptom Index
[7], a validated instrument that queries respondents
about 20 symptoms common among patients with
HIV, with possible responses of “I do not have this
symptom,” “[I have it but] it doesn’t bother me,” “it
bothers me a little,” “it bothers me,” and “it bothers
me a lot.” After completing the HIV Symptom Index,
participants were also asked to complete a single item
that queried beliefs about whether their symptoms
were attributable to antiretroviral medications (“Do
you think your symptoms are caused by the drugs you
take to treat your HIV infection?”). Surveys were com-
pleted between June 2002 and September 2004.
We sought to distinguish patients with substantial
side-effect burdens from patients with few or no side
effects. We reasoned that patients with substantial
side-effect burdens were those who: 1) endorsed one or
more of the symptoms in the HIV Symptom Index; (2)
endorsed a high degree of burden from at least one of
these symptoms (i.e., “it bothers me” or “it bothers me
a lot”); and 3) reported that symptoms were possibly
or deﬁnitely attributable to CART. For this analysis,
we considered patients who met all the three criteria
as having side effects from CART, whereas all other
patients were considered not to have side effects from
CART. We separately analyzed data from patients
reporting “possible” attribution of symptoms to
CART versus patients reporting “deﬁnite” attribution
of symptoms to CART.
Measuring Quality of Life
All patients in VACS completed the Medical Outcomes
Study SF-12, a widely used multidimensional health
status instrument [8]. Because our ultimate aim was to
yield results that could quantify the beneﬁts and harms
associated with CART, we assessed quality of life using
the construct of “utility,” a generic unidimensional
measure commonly used to represent quality of life
in decision analysis and cost-effectiveness analysis.
Brazier and Roberts [9] derived and validated a robust
conversion algorithm that estimates utilities based on
a six-dimensional subset of SF-12 questions—the
SF-6D––and we used this conversion algorithm to esti-
mate a utility for each VACS subject who completed
the SF-12. Although the SF-6D is scaled on a restricted
range, from 0.29 (worst possible health) to 1.00
(perfect health), it may have similar discriminatory
power compared to other approaches for eliciting
utilities [10].
Comparing Quality of Life of Patients with and without
Side Effects
We then compared the utilities of subjects who: 1) did
not have bothersome symptoms while taking CART;
2) had bothersome symptoms that they thought might
be due to CART; and 3) had bothersome symptoms that
they were conﬁdent were due to CART. We performed
univariate analyses as well as multivariable analyses
that controlled for other patient characteristics that
were likely to be associated a priori with quality of life
or that have been shown to be associatedwith quality of
life in previous reports [11–13]. Deﬁnitions of these
characteristics and details about their measurement are
described in more detail elsewhere [6].
We wanted to ensure that any quality-of-life
changes observed could not be explained by differences
in CD4 counts (i.e., patients experiencing side effects
may be less adherent or have other characteristics that
result in less favorable CD4 count trajectories, and the
CD4 count differences rather than the side effects
could lead to the observed utility discrepancies). For
this reason, we performed analyses stratiﬁed by CD4
count (<50, 50–199, 200–349, 350–499, and = 500
cells/ml). We used the CD4 count closest to the survey
date within a window of 6 months. Additionally, to
explore the degree to which decrements in utility from
CART varied by major demographic factors, we also
performed similar analyses stratiﬁed by age and race.
Because of insufﬁcient power to perform stratiﬁed mul-
tivariable analyses, we limited the stratiﬁed analyses to
univariate analyses.
Statistical Methods
To explore the adjusted association between CART
and utility, we used generalized linear models with the
linear portion log-transformed, and the errors assumed
to be normally distributed. The response variable
was utility and the predictor variables were age, sex,
race, hazardous alcohol consumption (deﬁned as an
AUDIT score >8) [14], homelessness in the 4 weeks
before the survey, substance abuse in the past year,
cigarette smoking in the past week, depression, and
type of CART (protease-inhibitor–based vs. non-
nucleoside-reverse-transcriptase-inhibitor–based vs.
triple-nucleoside–based). P-values less than 0.05 were
considered to be statistically signiﬁcant. We performed
all analyses by using SAS statistical software, version
9.1 (SAS Institute, Cary, NC). We estimated the R2 for
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the model using a published method for common non-
linear regression models [15].
Results
Patients in VACS were generally older (median age,
50.0 years), poorer (median household income =
$25,000/year), more likely to be non-White (73%),
and more likely to be male (97%) compared to those in
other observational HIV cohorts in the United States.
Substantial proportions of patients were hazardous
drinkers (18%), illicit drug users (28%), or homeless
(9%).
Of 2099 HIV-infected patients enrolled in VACS
at the time of this analysis, 2066 (98%) completed
patient surveys related to symptoms, and 1864 (89%)
had complete data available for analysis. Approxi-
mately two-thirds (66%) had perceived side effects
from CART. Of those, approximately half were unsure
about whether these symptoms were attributable to
medications (39% of all surveyed), whereas the
remainder (28% of all surveyed) were conﬁdent that
symptoms were attributable to medications.
In univariate analyses, patients with symptoms
had signiﬁcantly lower utilities than patients without
symptoms. Compared to patients reporting no symp-
toms, mean utilities were 0.06 (95% conﬁdence inter-
val [CI] 0.04–0.07) points lower among patients who
had symptoms but were unsure whether they were due
to CART. Similarly, utilities were on average 0.06
(95% CI 0.05–0.08) points lower for patients who
were conﬁdent that their symptoms were due to CART,
as compared to asymptomatic patients. Race, age, and
CD4 cell count were variably associated with changes
in utility from CART.
Multivariable analyses conﬁrmed the effect of per-
ceived CART side effects on utility (Table 1). Symp-
toms possibly attributable to side effects exacted a
mean decrement in utility of 0.09 (95% CI 0.07–0.10)
points, whereas symptoms deﬁnitely attributable
(according to patients) to CART side effects carried
a decrement in utility of 0.08 (95% CI 0.06–0.10)
points. Other statistically signiﬁcant factors associated
with SF-6D utilities were hazardous alcohol consump-
tion, drug use, smoking, homelessness, and race
(R2 = 0.12). Type of antiretroviral regimen was not
signiﬁcantly associated with utility.
In stratiﬁed analyses (Table 2), perceived side effects
continued to have a signiﬁcant impact on utility in all
CD4 strata except for the CD4 < 50 cells/ml category,
with mean decrements in utility ranging from 0.03 to
0.08 points for patients who were conﬁdent that their
symptoms were due to CART side effects. While this
was generally a robust ﬁnding, the association was
attenuated in the lowest CD4 stratum. Decrements in
utility did not appear to vary greatly by age or by race
(Table 2).
Discussion
In our national study of veterans with HIV, we
detected substantial decrements in quality of life that
were thought by patients to be due to side effects from
CART. The decrement of approximately 0.08 utility
units is clinically meaningful (e.g., greater than 0.04
utility units, the minimally important difference
reported for the SF-6D across 11 studies) [16], sub-
stantial (e.g., similar to the decrement in utility of
partial impotence or mild angina [17] and comparable
to the decrement in utility associated with homeless-
ness in our analysis), but not overwhelming (e.g., less
than the decrement in utility of complete impotence or
moderate angina [17]). The decrement in utility asso-
ciated with CART was fairly robust across different
patient subgroups.
While the beneﬁts of CART are comparatively easy
to quantify because of the abundance of relevant data,
the harms associated with CART are less certain. Pub-
lished studies reporting quality-of-life changes associ-
ated with CART have been unable to disaggregate the
impact of its side effects from its beneﬁt with regards to
HIV progression. In this study, we attempted to isolate
the impact of perceived side effects of CART. The
relative similarity of our results across CD4 strata
suggests that the decrements in utility that we found do
not result from differences in disease stage. That is,
our results are unlikely to reﬂect the possibility that
patients with side effects have worse CD4 levels as an
explanation for lower utilities. Interestingly, decre-
ments in utility of symptomatic patients who were
unsure whether their symptoms were due to CART
side effects were similar to those of patients who were
conﬁdent that their symptoms were due to CART.
Table 1 Multivariable analysis of utility for HIV-positive sub-




Intercept -0.27 (-0.30 to -0.24) <0.0001
Symptoms deﬁnitely attributable
(according to the patient)
to CART
-0.08 (-0.10 to -0.06) <0.0001|
Symptoms possibly attributable
(according to the patient)
to CART
-0.09 (-0.10 to -0.07) <0.0001
Age > 50 years -0.01 (-0.03 to 0.00) NS
Female sex† -0.00 (-0.05 to 0.05) NS
Hazardous alcohol consumption‡ -0.00 (-0.01 to -0.00) <0.0001
Recent drug use -0.02 (-0.04 to -0.01) 0.0122
Cigarette smoking -0.03 (-0.05 to -0.02) <0.0001
Homelessness within last 4 weeks -0.06 (-0.09 to -0.03) <0.0001
African American race 0.03 (0.02 to 0.05) 0.0001
CART containing PIs§ -0.01 (-0.02 to -0.01) NS
CART containing NNRTIs§ 0.01 (-0.01 to 0.02) NS
*Negative values connote disutility (worse quality of life).
†Effect was -0.002.
‡Effect was -0.004.
§Referent category was triple-nucleoside–based therapy.
CART, combination antiretroviral therapy; NNRTI, non-nucleoside reverse tran-
scriptase inhibitor; NS, not signiﬁcant at P < 0.05; PI, protease inhibitor.
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Our methods have several limitations. Even though
we controlled for a comprehensive set of potential
confounders, our cross-sectional approach precludes
inferring causality. We based our deﬁnition of side
effects on patients’ perceptions of whether symptoms
were in fact attributable to CART. This assumption has
not been well studied, and the validity of our work may
be lessened if patients misattributed their symptoms.
The landscape of HIV treatment changes rapidly, and
our ﬁndings may not apply to the newest CART regi-
mens. Finally, we estimated utilities based on SF-12
scores using the SF-6D rather than directly eliciting
them using a technique such as the standard gamble or
time trade-off. This method produces estimates that are
compressed into a comparatively narrow range (0.29–
1.00), with lower valuations for favorable health states
and higher valuations for unfavorable health states
compared to other approaches [18–20]. Nonetheless,
decrements in utility estimated using the SF-6D were
similar to decrements in utility estimated using other
instruments (e.g., EuroQol EQ-5D) in a representative
sample of 11,421 US adults across a wide range of
conditions and risk factors, increasing the likelihood
that our results are generalizable [10]. Furthermore, our
study’s limitations must be interpreted in the context of
its strengths, which stem from its large sample size and
its substantial augmentation of existing literature on
CARTand quality of life.Other than its sex distribution
(predominantly male), our cohort is more representa-
tive of the HIV epidemic in the United States than many
other large observational cohorts [21]. Our results may
be a useful tool for investigators who wish to quantify
harms and beneﬁts from CART for clinical care or for
cost-effectiveness analysis.
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